Alicia Levey is a Venture Partner in Versant’s San Francisco office where she is focused on both investing and new company creation. Alicia has an established track record as a company creator, operator and deal maker. She was most recently the President and COO at Pionyr Immunotherapeutics and was instrumental in the company’s collaboration and partial acquisition by Gilead Sciences and eventual merger with Ikena Oncology.
Prior to Pionyr, she served as both a member of the Versant Investment Team as an Operating Principal and as the business development lead for portfolio companies as CBO of Tempest Therapeutics (TPST) and VP of Business Development for Versant’s Inception Sciences drug discovery engine. During this time, she was a key contributor to multiple Series A investments including Novira, Audentes and Therachon.
Before moving to early biotech, Alicia worked as a Consultant and later a Project Leader in The Boston Consulting Group. She earned a Ph.D. in Cancer Biology from the Stanford University school of medicine where she focused on the development of novel activity-based inhibitors and probes in the laboratory of Dr. Matthew Bogyo.